Andrew Guggenhime - Feb 29, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
PRESIDENT AND CFO
Signature
/s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Feb 29, 2024
Transactions value $
-$271,532
Form type
4
Date filed
3/4/2024, 09:20 PM
Previous filing
Feb 22, 2024
Next filing
Mar 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +20K +25.17% $0.00 99.5K Feb 29, 2024 Direct F1
transaction PCVX Common Stock Tax liability -$272K -3.8K -3.82% $71.55 95.7K Mar 2, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +90K $0.00 90K Feb 29, 2024 Common Stock 90K $73.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F3 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.